Payment overview · 2025
General Payments
$1,226.73
64 reported records · 21 companies
Healthcare provider profile · identity verified
Hammad H. Bokhari, MD
Allopathic & Osteopathic Physicians|Family Medicine · JEFFERSONVILLE, IN · NPI 1104832161
Verified facts
What the public records show
CMS Open Payments records show Hammad H. Bokhari, MD received $1,226.73 in general payments during 2025 across 64 reported records.
ABBVIE INC. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $256.59 | 20.9% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $152.10 | 12.4% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $113.10 | 9.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $106.98 | 8.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.38 | 7.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.58 | 4.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.98 | 4.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.25 | 4.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $47.13 | 3.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.80 | 3.7% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $38.12 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.97 | 3.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $29.85 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.74 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.59 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.88 | 1.6% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18.65 | 1.5% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $16.99 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.30 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.10 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $13.65 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,226.73 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $168.44 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $139.84 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.95 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $106.98 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.76 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.05 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.05 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.58 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $55.98 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $55.98 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.52 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $47.13 | 3 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $38.12 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.97 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $36.63 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $36.63 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.20 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.13 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.13 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 66 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 505 | 112 |
| Gabapentin | Gabapentin | 411 | 78 |
| Montelukast Sodium | Montelukast Sodium | 321 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 266 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 79 |
| Potassium Chloride | Potassium Chloride | 236 | 73 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 230 | 46 |
| Lisinopril | Lisinopril | 208 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 42 |
| Omeprazole | Omeprazole | 159 | 40 |
| Meloxicam | Meloxicam | 157 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 45 |
| Methocarbamol | Methocarbamol | 155 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 35 |
| Furosemide | Furosemide | 133 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 38 |
| Celecoxib | Celecoxib | 127 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 25 |
| Pregabalin | Pregabalin | 117 | 26 |
| Topiramate | Topiramate | 113 | 26 |
| Metformin Hcl | Metformin Hcl | 105 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 32 |
| Aripiprazole | Aripiprazole | 99 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 28 |
| Dexamethasone | Dexamethasone | 86 | 65 |
| Losartan Potassium | Losartan Potassium | 80 | 23 |
| Levofloxacin | Levofloxacin | 79 | 62 |
| Ozempic | Semaglutide | 79 | 14 |
| Carvedilol | Carvedilol | 77 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 18 |
| Farxiga | Dapagliflozin Propanediol | 74 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 12 |
| Temazepam | Temazepam | 71 | 13 |
| Linzess | Linaclotide | 66 | 13 |
| Trazodone Hcl | Trazodone Hcl | 64 | 19 |
| Baclofen | Baclofen | 62 | 11 |
| Azithromycin | Azithromycin | 61 | 45 |
| Buspirone Hcl | Buspirone Hcl | 61 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 24 |
| Simvastatin | Simvastatin | 60 | 17 |
| Tramadol Hcl | Tramadol Hcl | 60 | 16 |
| Eliquis | Apixaban | 59 | 12 |
| Glipizide Er | Glipizide | 58 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 57 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 16 |
| Metformin Hcl Er | Metformin Hcl | 56 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 55 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | 12 |
| Glipizide | Glipizide | 53 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 15 |
| Alprazolam | Alprazolam | 47 | 15 |
| Vraylar | Cariprazine Hcl | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Prednisone | Prednisone | 44 | 33 |
| Memantine Hcl | Memantine Hcl | 42 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 21 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trokendi Xr | Topiramate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,226.73 · 64 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, ARISTADA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Dyanavel XR, FANAPT, FARXIGA, FREESTYLE LIBRE 3, HETLIOZ, JARDIANCE, Kerendia, LINZESS, LYBALVI, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, REPATHA, REXULTI, Rybelsus, Senza, Sunosi, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error